GlobeNewswire: Atara Biotherapeutics, Inc. Contains the last 10 of 178 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:41:31ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/02/27/1991801/0/en/Atara-Biotherapeutics-Announces-Fourth-Quarter-and-Full-Year-2019-Financial-Results-and-Recent-Clinical-Operational-and-Strategic-Progress.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress2020-02-27T12:30:00Z<![CDATA[Company to host conference call today at 8:00 a.m. EST Company to host conference call today at 8:00 a.m. EST]]>https://www.globenewswire.com/news-release/2020/02/21/1988803/0/en/Atara-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-C-4.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)2020-02-21T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Kristin Yarema, its Chief Commercial Officer.]]>https://www.globenewswire.com/news-release/2020/02/20/1988211/0/en/Atara-Biotherapeutics-to-Participate-at-Two-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences2020-02-20T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's President and Chief Executive Officer, will participate at two upcoming investor conferences in March:]]>https://www.globenewswire.com/news-release/2020/02/19/1987305/0/en/Atara-Biotherapeutics-to-Announce-Fourth-Quarter-and-Full-Year-2019-Financial-Results-on-Thursday-February-27-2020.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 20202020-02-19T21:00:00Z<![CDATA[Live Conference Call and Webcast at 8:00 a.m. EST Live Conference Call and Webcast at 8:00 a.m. EST]]>https://www.globenewswire.com/news-release/2020/02/05/1980250/0/en/Atara-Biotherapeutics-Names-Kristin-Yarema-as-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer2020-02-05T13:30:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today named Kristin Yarema as Chief Commercial Officer, effective as of February 18, 2020.]]>https://www.globenewswire.com/news-release/2020/01/12/1969201/0/en/Atara-Biotherapeutics-to-Present-2020-Key-Milestones-and-Progress-in-Bringing-Off-The-Shelf-Allogeneic-T-Cell-Immunotherapies-to-Patients-in-Need-at-the-38th-Annual-J-P-Morgan-Heal.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference2020-01-12T19:00:00Z<![CDATA[Key milestones anticipated across Atara’s four strategic priorities in 2020]]>https://www.globenewswire.com/news-release/2019/12/09/1957999/0/en/Atara-Biotherapeutics-Reports-Updated-Long-Term-Clinical-Results-from-a-Tab-cel-Multicenter-Expanded-Access-Protocol-EAP-Study-for-Patients-with-Epstein-Barr-Virus-Associated-Post-.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting2019-12-09T15:00:00Z<![CDATA[61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® (tabelecleucel) EAP study]]>https://www.globenewswire.com/news-release/2019/11/26/1952909/0/en/Atara-Biotherapeutics-to-Participate-at-Evercore-ISI-Second-Annual-HealthCONx-Conference.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference2019-11-26T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI Second Annual HealthCONx Conference on Tuesday, December 3, 2019 at 3:50 p.m. EST. The conference will be held at the Four Seasons Hotel in Boston, MA.]]>https://www.globenewswire.com/news-release/2019/11/07/1943050/0/en/Atara-Biotherapeutics-Announces-Third-Quarter-2019-Financial-Results-and-Recent-Clinical-Operational-and-Strategic-Progress.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress2019-11-07T12:30:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the third quarter of 2019 and recent business highlights.]]>https://www.globenewswire.com/news-release/2019/11/06/1942272/0/en/Atara-Biotherapeutics-to-Present-Tab-cel-Long-Term-Clinical-Outcomes-from-a-Multicenter-Expanded-Access-Protocol-EAP-Study-for-Patients-with-Epstein-Barr-Virus-Associated-Post-Tran.html?f=22&fvtc=4&fvtv=23495Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting2019-11-06T14:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it will present long-term tab-cel® (tabelecleucel) clinical outcomes from a multicenter Expanded Access Protocol (EAP) study for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD). These results, along with findings described in three additional abstracts, will be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, to be held December 7-10, 2019, in Orlando, Florida.]]>